Charles Schwab Investment Management Inc. Buys 9,664 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS)

Charles Schwab Investment Management Inc. boosted its holdings in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 4.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 213,599 shares of the company’s stock after acquiring an additional 9,664 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.43% of Mineralys Therapeutics worth $2,587,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. American Century Companies Inc. lifted its position in shares of Mineralys Therapeutics by 3.2% during the 2nd quarter. American Century Companies Inc. now owns 743,140 shares of the company’s stock valued at $8,695,000 after acquiring an additional 23,170 shares during the period. Jennison Associates LLC grew its stake in shares of Mineralys Therapeutics by 1.9% in the 3rd quarter. Jennison Associates LLC now owns 696,280 shares of the company’s stock worth $8,432,000 after acquiring an additional 13,023 shares in the last quarter. Nantahala Capital Management LLC grew its stake in shares of Mineralys Therapeutics by 60.1% in the 2nd quarter. Nantahala Capital Management LLC now owns 532,506 shares of the company’s stock worth $6,230,000 after acquiring an additional 200,000 shares in the last quarter. Driehaus Capital Management LLC grew its stake in shares of Mineralys Therapeutics by 40.4% in the 2nd quarter. Driehaus Capital Management LLC now owns 257,371 shares of the company’s stock worth $3,011,000 after acquiring an additional 74,074 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in Mineralys Therapeutics by 72.5% during the second quarter. Bank of New York Mellon Corp now owns 84,762 shares of the company’s stock valued at $992,000 after buying an additional 35,634 shares during the period. 84.46% of the stock is owned by institutional investors.

Mineralys Therapeutics Trading Down 2.2 %

Shares of Mineralys Therapeutics stock opened at $11.90 on Monday. Mineralys Therapeutics, Inc. has a 12-month low of $7.29 and a 12-month high of $16.91. The company has a market cap of $592.26 million, a price-to-earnings ratio of -3.64 and a beta of 1.55. The company’s 50-day moving average price is $13.25 and its 200-day moving average price is $12.59.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its quarterly earnings results on Monday, November 11th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.30). During the same period in the previous year, the firm earned ($0.57) EPS. On average, sell-side analysts predict that Mineralys Therapeutics, Inc. will post -3.63 earnings per share for the current year.

Insider Activity at Mineralys Therapeutics

In related news, insider David Malcom Rodman sold 25,482 shares of Mineralys Therapeutics stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $15.03, for a total value of $382,994.46. Following the transaction, the insider now directly owns 135,974 shares of the company’s stock, valued at $2,043,689.22. The trade was a 15.78 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Adam Scott Levy sold 10,757 shares of Mineralys Therapeutics stock in a transaction on Friday, October 11th. The stock was sold at an average price of $13.57, for a total transaction of $145,972.49. Following the completion of the transaction, the chief financial officer now directly owns 236,854 shares in the company, valued at approximately $3,214,108.78. The trade was a 4.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 51,510 shares of company stock valued at $735,431 over the last three months. 33.24% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Mineralys Therapeutics in a research report on Tuesday, November 12th.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.